HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tobacco Law Means Drug Sponsor Opportunities May Not Stop At Cessation

This article was originally published in The Tan Sheet

Executive Summary

The tobacco control act prompts FDA to consider new indications - such as smoking reduction - for smoking cessation products, which could lead to new criteria for application approval

You may also be interested in...

FDA Will Mull OTC Smoking Cessation Long-Term Use As Support Builds

Participants at an FDA workshop will consider issues that could influence whether the agency extends the use of nicotine-replacement therapies beyond the current 12-week indication

U.K. NRT Harm Reduction Indication Could Be Model For U.S.

The U.K.'s harm reduction indication for a nonprescription nicotine replacement therapy inhaler could bode well for GlaxoSmithKline's request that FDA allow a similar change for NRT products in the U.S

Tobacco Firm Reynolds Enters NRT Market With Niconovum Buy

Tobacco giant Reynolds American Inc.'s purchase of Swedish NRT firm Niconovum will put the company in the business of serving both smokers and quitters

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts